T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor invading ...
SEQTOR trial shows comparable PFS for STZ/5-FU followed by everolimus and the reverse sequence in advanced pancreatic NETs. STZ/5-FU demonstrated higher response rates, beneficial for rapid tumor ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...
Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or ...
Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved a label expansion for its best-selling cancer therapy Cabometyx (cabozantinib) to include patients aged 12 years of age and ...
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. Exelixis disclosed the cancellation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results